Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495464 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1304066 | 0.85 | RAB9A (0.52) | SMN1; SMN2MEN1KMT2AALDH1A1RAB9A | |
| Propionic Acid SCHEMBL20899068 | 0.84 | LDHA (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL937721 | 0.83 | CYP11B1 (0.47) | SMN1; SMN2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL11679569 | 0.82 | NPC1 (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL903602 | 0.80 | RAB9A (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL11683554 | 0.79 | KDM1A (0.53) | HSD17B1HSD17B2 | |
| SCHEMBL6648525 | 0.78 | MAPK1 (0.46) | SMN1; SMN2MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL9446910 | 0.78 | BCHE (0.47) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL11681190 | 0.78 | KDM1A (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| CN-104045625-A | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER | 2014-09-17 | — | — | CN | disclosed |
| WO-2013153479-A2 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-10 | — | — | US | disclosed |
| CN-101679235-A | Azetidine derivatives and their use as prostaglandin E2 antagonists | PFIZER LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2155666-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139287-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| WO-2002074267-A1 | NOVEL DYEING COMPOSITIONS FOR THE DYEING OF KERATIN FIBRES COMPRISING 6-MEMBERED HETEROCYCLIC HYDRAZONE COMPOUNDS AS AN OXIDATION BASE | L'OREAL (FR) | 2002-09-26 | — | — | WO | disclosed |
| US-4402958-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-09-06 | — | — | US | disclosed |
| US-4046763-A | INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | SMN1; SMN2 4235/4885MEN1 1101/4885KMT2A 2961/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | SMN1; SMN2 4692/4885MEN1 2850/4885KMT2A 4770/4885 |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | SMN1; SMN2 1788/4885MEN1 3206/4885KMT2A 3326/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | SMN1; SMN2 4586/4885MEN1 2885/4885KMT2A 4589/4885 |
| US-20080280877-A1 | Azetidines | PTGER2, PTGER1, PTGDR2 | SMN1; SMN2 3965/4885MEN1 929/4885KMT2A 659/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | SMN1; SMN2 1164/4885MEN1 2885/4885KMT2A 2949/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | SMN1; SMN2 4235/4885MEN1 1101/4885KMT2A 2961/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | SMN1; SMN2 2499/4885MEN1 2809/4885KMT2A 3704/4885 |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | SMN1; SMN2 4470/4885MEN1 4037/4885KMT2A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.